RecruitingNCT05218785

Treatment of Gastrocnemius Tightness and Subsequent Chronic Plantar Fasciitis with Botulinum Toxin a

Botulinum Toxin Injection As Treatment for Proximal Medial Gastrocnemius Muscle Tightness with Subsequent Chronic Plantar Fasciitis - a Prospective Clinical Cohort Study


Sponsor

Oslo University Hospital

Enrollment

40 participants

Start Date

Jan 13, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

This prospective clinical cohort study will follow 40 patients who recieve botulinum toxin A treatment for proximal medial gastrocnemius tightness with subsequent Chronic Plantar Fasciitis for two years. Three injections of botulinum toxin (75IU) will be administered with intervals of three months. Participants will be followed at baseline, 3 months, 6 months, 1 year and 2 years with Patient Related Outcome Measures (PROMS) and physical test (Ergotest and ankle dorsiflexion).


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria6

  • Age 18-75 years.
  • An isolated gastrocnemius contracture must be verified with the Silfverskiölds test before inclusion.
  • Diagnosis plantar fasciitis verified clinically by an orthopaedic surgeon.
  • Diagnosis verified by MRI. MRI criteria: Thickening of the plantar fascia, oedema in the calcaneus, pathological signal changes in the plantar fascia (35)
  • Duration of symptoms must be at least 12 months prior to first BTA injection.
  • Conventional Physical Therapy must have been tried at least three months without a significant reduction of symptoms in the affected foot.

Exclusion Criteria7

  • Previously undergone surgery for plantar fasciitis.
  • Patients with severe talocrural pathology or serious malalignment of foot and ankle
  • Severely reduced peripheral circulation
  • History of alcoholism, drug abuse, psychological or other emotional problems likely to jeopardize informed consent.
  • Patients with a contraindication/non-compliance for MRI examination.
  • History of allergic reaction/anaphylactic reaction or other contraindication to botulinum toxin.
  • Not able to read and/or speak a Scandinavian language or English adequately.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBotox

75 U in medial gastrocbemius head. x 3


Locations(1)

Oslo University Hospital, Orthopedic Department Ullevål

Oslo, Oslo County, Norway

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05218785


Related Trials